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ABSTRACT
Background Germline mutations in CDH1 are associated
with hereditary diffuse gastric cancer; lobular breast
cancer also occurs excessively in families with such
condition.
Method To determine if CDH1 is a susceptibility gene
for lobular breast cancer in women without a family
history of diffuse gastric cancer, germline DNA was
analysed for the presence of CDH1 mutations in 318
women with lobular breast cancer who were diagnosed
before the age of 45 years or had a family history of
breast cancer and were not known, or known not, to be
carriers of germline mutations in BRCA1 or BRCA2.
Cases were ascertained through breast cancer registries
and high-risk cancer genetic clinics (Breast Cancer
Family Registry, the kConFab and a consortium of breast
cancer genetics clinics in the United States and Spain).
Additionally, Multiplex Ligation-dependent Probe
Ampliﬁcation was performed for 134 cases to detect
large deletions.
Results No truncating mutations and no large deletions
were detected. Six non-synonymous variants were found
in seven families. Four (4/318 or 1.3%) are considered to
be potentially pathogenic through in vitro and in silico
analysis.
Conclusion Potentially pathogenic germline CDH1
mutations in women with early-onset or familial lobular
breast cancer are at most infrequent.
INTRODUCTION
CDH1 encodes the cellecell adhesion molecule,
E-cadherin. Loss of expression of E-cadherin contrib-
utes to the inﬁltrative and metastatic behaviours of
cancers. Germline loss-of-function mutations in
CDH1 are associated with the autosomal dominant
cancer-predisposition syndrome, hereditary diffuse
gastric cancer (HDGC) (OMIM: +192090).
1 2 In
HDGC, germline mutations in CDH1 confer a high
lifetime risk of DGC for male and female mutation
carriers.
34Additionally, female mutation carriers
have a 39%e52% lifetime risk of breast cancer,
although these estimates have wide conﬁdence
intervals.
34Multiple reports have established the
association of lobular breast cancer (LBC) with
HDGC and germline mutations in CDH1.
4e7
Previously, we identiﬁed one carrier of a germline
truncating CDH1 mutation among 23 women with
LBC known not to carry germline BRCA1 and
BRCA2 mutations.
8 This case series included
women diagnosed with LBC at a young age
(&45 years) and women diagnosed with LBC at
any age with a family history of breast cancer but
not of gastric cancer (1/23 or 4.3%).
8 The same
mutation was subsequently conﬁrmed in a relative
of the mutation carrier who also had LBC. This
coincidence of CDH1 mutations and hereditary
LBC led us to assess the prevalence of CDH1
mutations in a series of 318 women with early-
onset LBC or a family history of breast cancer,
consistent with hereditary LBC, ascertained
through breast cancer registries and high-risk cancer
genetic clinics (Breast Cancer Family Registry
(Breast CFR), the kConFab and a consortium of
breast cancer genetics clinics in the United States
and Spain).
MATERIALS AND METHODS
Patient accrual, preparation of DNA and CDH1
sequencing, deletion analysis, mutation validation,
and protein structure and functional analyses are
described in the online supplementary material.
RESULTS
Germline DNAs from 327 eligible patients with
LBC were analysed for variants in CDH1, but for
nine samples, several exons failed to amplify,
yielding incomplete results. Sequence analysis for
heterozygous variants in the 318 patients with
complete results did not detect any protein-trun-
cating mutations. Multiplex Ligation-dependent
Probe Ampliﬁcation analyses in 134 patients did
not reveal any large deletions in CDH1.
We did ﬁnd 10 patients with non-synonymous
variants. One non-synonymous change, c.1774G/A,
p.A592T, was found in two patients and is a known
germline variant that is not associated with risk of
familial breast cancer or HDGC.
9 10 The variant,
c.2494G/A, p.V832M, which had previously been
identiﬁed in a patient with HDGC and was func-
tionally characterised as a pathogenic mutation,
11 12
was found in a woman who was diagnosed as having
LBC at the age of 43 years and had a family history of
ductal breast cancer in a sister and unspeciﬁed breast
cancer in a maternal aunt. Segregation analysis has
not yet been performed. The remaining non-synon-
y m o u sv a r i a n t sw e r en o v e la n dd i dn o ta p p e a ri na n y
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Short reportpublic databases. These variants were c.8C/G, p.P3R;
c.1223C/T, p.A408V; c.1297G/A, p.D433N; c.1813A/G, p.
R695G and c.88 C/A, p.P30T, which were found in two patients
not known to be related. There was no family history of gastric
cancer for any of the patients who carried novel non-synonymous
variants (table 1).
Nine unreported novel silent changes were identiﬁed: ﬁve
synonymous variants in exons and four variants in introns. Two
of these novel changes were found in more than one patient
(data not shown).
We performed several tests to assess the likelihood that any of
the non-synonymous variants resulted in a loss of normal
function. Web-based software (Sorting Intolerant from Tolerant,
SIFT) that predicts whether the amino acid change conferred by
non-synonymous variants might alter protein structure, and
thus possibly function, indicated that all but one variant,
c.8C/G, p.P3R, which occurred in the signal peptide of the pre-
protein, should be tolerated and therefore is unlikely to be
pathogenic. Moreover, web-based software (Berkeley Drosophila
Genome Project, Splice Site Prediction by Neural Network,
Berkeley, Calif) did not predict alteration of splicing by any of
the novel synonymous or non-synonymous variants or intronic
variants identiﬁed.
The likely pathogenicities of the novel non-synonymous
variants were further assessed by analysing the predicted effects
of amino acid changes on the three-dimensional structure of
E-cadherin. Because the coordinates of the three-dimensional
structure of the ectodomain of E-cadherin were not available, we
used the model of the closely related paralog, C-cadherin, to
predict likely changes in the structure. One of the mutations,
c.1223C/T, p.A408V, changes the alanine residue, which is
well-conserved in this family of proteins, to bulkier valine and is
located in calcium ion-binding extracellular domain 3.
Surface modelling of the mutated protein indicated that this
bulky valine could conceivably alter the binding pocket of one of
three calcium ions that mediate homotypic cadherin domain
interactions (Supplementary ﬁgure 1). Another mutation,
c.1297G/A, p.D433N, was also found to be located in close
proximity to this calcium-binding site (Supplementary ﬁgure 1).
Because the c.8C/G, p.P3R variant occurs in the signal peptide
of the precursor protein and had been predicted to be patho-
genic, we hypothesised that this variant could result in misloc-
alisation or lack of expression of E-cadherin on the cell surface.
To test this hypothesis, we expressed normal E-cadherin or each
of the mutated versions of the protein in cells lacking endoge-
nous E-cadherin. As seen in Supplementary ﬁgure 2, E-cadherin
mutated with the c.8C/G, p.P3R variant did exhibit membrane
localisation, indicating that protein localisation was not grossly
affected by this variant. Additionally, the other novel
non-synonymous variants also demonstrated membrane local-
isation (data not shown). However, because the levels at which
we expressed E-cadherin were not physiological, it is possible
that subtle effects of the mutations could have been missed.
Taking into account the in vitro and in silico analysis, four
non-synonymous variants (c.8C/G, p.P3R; c.1223C/T,
p.A408V; c.1297G/A, p.D433N and c.2494G/A, p.V832M)
are considered potentially pathogenic (4/318 or 1.3%). If we only
consider the subset of patients who have been tested and found
not to carry BRCA1 or BRCA2 mutations, the prevalence of
potentially pathogenic variants is 1.6% (4/246).
DISCUSSION
Germline mutations in CDH1 are associated with a substan-
tively increased risk of LBC.
8 This study found that the preva-
lence of potentially pathogenic CDH1 variants is low in patients
with early-onset or familial LBC who do not report a clear
Table 1 Clinical characteristics of patients with LBC with non-synonymous variants
Non-synonymous variant
Criteria
1o r2
BRCA1/2 mutation
status
Age at
diagnosis Family history (age at diagnosis)
c.8C/G, p.P3R 1 Negative 38 years Maternal aunt¼breast cancer
(46 years)
Maternal aunt¼breast cancer
(67 years)
Maternal cousin¼breast cancer
(42 years)
Mother¼retroperitoneal tumour
Paternal grandmother¼breast cancer
c.88 C/A, p.P30T
(two patients)
1 Unknown 40 years
2 Negative 47 years Paternal aunt¼breast cancer
(40 years)
Female paternal cousin¼breast
cancer (40 years)
Male paternal cousin¼breast cancer
(50 years)
Female paternal cousin¼breast
cancer (47 years)
c.1223C/T, p.A408V 1 Negative 44 years No cancers
c.1297G/A, p.D433N 1 Negative 41 years Paternal grandmother¼intestinal
cancer
Maternal grandmother¼lung cancer
Maternal grandfather¼mouth cancer
c.1813A/G, p.R605G 1 Unknown 42 years Mother¼breast cancer (60 years)
Maternal uncle¼pancreatic cancer
(64 years)
c. 2494G/A, p.V832M
(known missense mutation in
HDGC)
1 Negative 43 years Sister¼ductal breast cancer
Maternal aunt¼breast cancer
Paternal uncle¼leukaemia
Paternal grandmother¼colon cancer
Clinical history of patients with LBC in whom potentially pathogenic variants were identiﬁed. There was no known family history of
gastric cancer in these patients.
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Short reportfamily history of DGC. The large sample size increases the
likelihood that the results in this setting are precise. This study
highlights the utility of publicly available registries as valuable
resources of clinically and epidemiologically annotated families
with accompanying germline DNA for future research in this
ﬁeld.
It remains possible that CDH1 mutations are present in rare
families with multiple LBCs even without gastric cancer.
Although the patients in the present study had conﬁrmed LBC,
we were unable to conﬁrm the pathology of the breast cancers in
the relatives, which remained unspeciﬁed for most of the
patients. Additionally, because 72 patients (23%) were not tested
for mutations in BRCA1 and BRCA2 (table 2), it is possible that
some BRCA1 and BRCA2 mutation carriers were included in this
study. The likelihood, however, is low because most early-onset
and familial breast cancers are not accounted for by germline
mutations in BRCA1 and BRCA2.
13 14 We had previously
reported a pathogenic truncating CDH1 mutation in a patient
with LBC and her mother, who had both developed LBC before
age 45 years.
8 However, our data suggest that CDH1-associated
LBC without gastric cancer must be very rare because so few
were identiﬁed in the present study among women highly
selected for early-onset LBC or LBC with additional breast
cancer in the family. It might still be prudent to consider
germline CDH1 testing in families with conﬁrmed multiple
cases of early-onset LBC, even in the absence of a family history
of gastric cancer. In such families, and in those with a reported
but unspeciﬁed history of abdominal cancer, the possibility of
ovarian cancer would lead to BRCA1 and then BRCA2 testing,
and the possibility of DGC should lead to consideration of
CDH1 testing. For women with LBC, it is important to look for
a family history of gastric cancer so that HDGC families will be
recognised and offered appropriate management for their risk of
DGC.
In our study, the pathogenic germline variant, p.V832M, was
identiﬁed in a patient with LBC without a family history of
gastric cancer. This variant was initially found to segregate with
disease in a Japanese family where the proband had DGC at age
61 years and four of seven siblings, the mother and a niece all
had unspeciﬁed gastric cancer. Functional characterisation in
Chinese hamster ovary cells demonstrated reduced cell aggre-
gation and increased invasive properties of the mutant compared
with wild-type E-cadherin.
12 Although this effect was not
reproduced in functional characterisation undertaken in human
squamous epithelial cells,
15 further work has demonstrated
a mechanism by which this mutation might confer a pathogenic
effect, through loss of type Ig phosphatidylinositol phosphate
kinase binding, causing abnormal E-cadherin trafﬁcking and
adherens junction formation.
16
The novel non-synonymous variants in this study were not
conﬁrmed by our in vitro and in silico studies to be pathogenic,
although further investigation needs to be done on the sugges-
tive evidence that the variants c.1223C/T, p.A408V and
c.1297G/A, p.D433N might interfere with calcium-dependent
homophilic binding. Also, a novel, presumably rare variant (c.88
C/A, p.P30T) was shared by two patients with LBC from one
of the high-risk breast cancer clinics: this could imply that this
variant is linked to the disease and that these two women are
distantly related. Alternatively, this may represent a rare variant
not associated with LBC, whose distribution in the normal
population frequency will become known as the genomes of
more people are sequenced. Data from the 1000 Genomes Project
may also be helpful in the interpretation of the signiﬁcance of
these variants, through demonstration of the full proﬁle of
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Short reportnormal variation within CDH1 and their distribution in and
across populations.
Although a combination of LBC and DGC is strongly indic-
ative of germline mutations in CDH1, in the absence of a history
of DGC, CDH1 mutations appear to be extremely rare. It is
possible that CDH1 mutations would be more often identiﬁed in
families with multiple documented invasive lobular or mixed
ductal/lobular breast cancers in the absence of DGC, but such
families are uncommon. Therefore, a history of early-onset or
familial LBC should trigger speciﬁc questions around a history of
abdominal cancer.
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